Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021PRNewsWire • 07/22/21
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic MastocytosisPRNewsWire • 06/16/21
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid TumorsPRNewsWire • 05/19/21
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific OfficerPRNewsWire • 05/17/21
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million DealSeeking Alpha • 05/03/21
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021PRNewsWire • 04/22/21
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021PRNewsWire • 04/11/21
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021PRNewsWire • 04/10/21
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021PRNewsWire • 04/05/21
Blueprint Medicines (BPMC) Up 2.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/19/21
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021PRNewsWire • 03/10/21
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/17/21